159 related articles for article (PubMed ID: 33096917)
1. Reversal of Ovarian Cancer Cell Lines Multidrug Resistance Phenotype by the Association of Apiole with Chemotherapies.
Afonso de Lima C; de Souza Bueno IL; Nunes Siqueira Vasconcelos S; Sciani JM; Ruiz ALTG; Foglio MA; Carvalho JE; Barbarini Longato G
Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33096917
[TBL] [Abstract][Full Text] [Related]
2. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
3. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines.
Nielsen D; Skovsgaard T
Biochim Biophys Acta; 1992 Jul; 1139(3):169-83. PubMed ID: 1352705
[TBL] [Abstract][Full Text] [Related]
5. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
7. Effects of Myristicin in Association with Chemotherapies on the Reversal of the Multidrug Resistance (MDR) Mechanism in Cancer.
Seneme EF; Dos Santos DC; de Lima CA; Zelioli ÍAM; Sciani JM; Longato GB
Pharmaceuticals (Basel); 2022 Oct; 15(10):. PubMed ID: 36297344
[TBL] [Abstract][Full Text] [Related]
8. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
9. Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds.
Kars MD; Iseri OD; Gündüz U; Ural AU; Arpaci F; Molnár J
Anticancer Res; 2006; 26(6B):4559-68. PubMed ID: 17201178
[TBL] [Abstract][Full Text] [Related]
10. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance.
Barancík M; Bohácová V; Sedlák J; Sulová Z; Breier A
Eur J Pharm Sci; 2006 Dec; 29(5):426-34. PubMed ID: 17010577
[TBL] [Abstract][Full Text] [Related]
11. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
[TBL] [Abstract][Full Text] [Related]
12. The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance.
Cao Z; Wright M; Cheng J; Huang X; Liu L; Wu L; Yang P
Oncol Rep; 2014 Sep; 32(3):1211-7. PubMed ID: 25017650
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological strategies for overcoming multidrug resistance.
Nobili S; Landini I; Giglioni B; Mini E
Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
[TBL] [Abstract][Full Text] [Related]
14. Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6.
Zhu HJ; Wang JS; Guo QL; Jiang Y; Liu GQ
Biol Pharm Bull; 2005 Oct; 28(10):1974-8. PubMed ID: 16204958
[TBL] [Abstract][Full Text] [Related]
15. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
[TBL] [Abstract][Full Text] [Related]
16. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells.
Li C; Guan X; Xue H; Wang P; Wang M; Gai X
Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760
[TBL] [Abstract][Full Text] [Related]
17. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
18. Wilforine resensitizes multidrug resistant cancer cells via competitive inhibition of P-glycoprotein.
Chang YT; Lin YC; Sun L; Liao WC; Wang CCN; Chou CY; Morris-Natschke SL; Lee KH; Hung CC
Phytomedicine; 2020 Jun; 71():153239. PubMed ID: 32447245
[TBL] [Abstract][Full Text] [Related]
19. SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance.
Barancík M; Bohácová V; Kvackajová J; Hudecová S; Krizanová O; Breier A
Eur J Pharm Sci; 2001 Aug; 14(1):29-36. PubMed ID: 11457647
[TBL] [Abstract][Full Text] [Related]
20. Mechanism Underlying the Reversal of Drug Resistance in P-Glycoprotein-Expressing Leukemia Cells by Pinoresinol and the Study of a Derivative.
González ML; Vera DMA; Laiolo J; Joray MB; Maccioni M; Palacios SM; Molina G; Lanza PA; Gancedo S; Rumjanek V; Carpinella MC
Front Pharmacol; 2017; 8():205. PubMed ID: 28487651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
